Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocryst Pharma Inc (NQ: BCRX )

11.23 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 11.23
Bid (Size) 11.14 (1)
Ask (Size) 12.30 (1)
Prev. Close 11.23
Today's Range 11.23 - 11.23
52wk Range 7.610 - 19.99
Shares Outstanding 185,583,896
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Stocks Rally as Major Indexes Look to End Losing Streaks
All three major indexes are set to snap three consecutive weeks of losses on Friday, as stocks surge midday. 
Via Talk Markets
BioCryst Gets FDA Fast Track Designation For Bone Formation Disorder Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BioCryst Pharmaceuticals's (NASDAQ: BCRX) lead drug candidate BCX9250 for the prevention of heterotopic ossification... 
Via Benzinga

Performance

YTD
-20.18%
-20.18%
1 Month
+7.88%
+7.88%
3 Month
-31.82%
-31.82%
6 Month
-11.30%
-11.30%
1 Year
-30.81%
-30.81%

More News

Read More
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
Via InvestorPlace
BioCryst's Voluntary Pause Of Rare Blood Disorder Trial Turns Into FDA Clinical Hold
Via Benzinga
Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Recap: BioCryst Pharmaceuticals Q1 Earnings
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Via Benzinga
7 Top-Rated Biotech Stocks to Buy for Q2
Via InvestorPlace
What 4 Analyst Ratings Have To Say About BioCryst Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
Via Benzinga
28 Biggest Movers From Yesterday
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Oppenheimer Maintains Outperform Rating for BioCryst Pharmaceuticals, Lowers Price Target To $16
Via Benzinga
Why BioCryst Pharmaceuticals Stock Is Falling
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Falls 150 Points; Crude Oil Rises 2%
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
28 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Mid-Day Market Update: Dow Jumps Over 200 Points; Sunshine Biopharma Shares Slide
Via Benzinga
Mid-Morning Market Update: Markets Edge Lower; US Wholesale Inventories Rise 2.5% In February
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.